September 26, 2025
Bayer AG shareholders have asked a California federal judge to give final approval of its $38 million settlement with the German multinational to end claims it downplayed litigation risks related to the weedkiller Roundup, saying the deal, which seeks over $10 million in attorney fees, is fair.
A hearing for the motions is set for Oct. 30. The parties notified the court that they had reached a settlement in the case in February, and the deal was preliminarily approved in June, according to the suit’s docket.
U.S. District Judge Richard Seeborg said the deal appeared to be “fair, reasonable and adequate” when initially approving the deal in June.
In a motion requesting 27% of the settlement fund in attorney fees, lead counsel said the nearly $10.3 million payment would represent “a reasonable and justifiable upward adjustment from the 25% benchmark” used in the Ninth Circuit. Among other things, the attorneys noted they had dedicated nearly 15,000 hours of professional time to the case.
The attorneys also called their request for almost $3.3 million in expenses “reasonable both in scope and magnitude.”
If granted final approval, the settlement would put an end to five years of litigation.
. . .
The investors are represented by Carol V. Gilden, Steven J. Toll, Christopher Lometti and Benjamin F. Jackson of Cohen Milstein Sellers & Toll PLLC and Nicole Lavallee and Alexander S. Vahdat of Berman Tabacco.
Read Bayer Investors Seek Final OK Of $38M Settlement, Atty Fees.